コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 to inform decisions on withholding adjuvant systemic chemotherapy.
2 rnally-cooled electrodes in association with systemic chemotherapy.
3 matic disease sites as well as intra-CSF and systemic chemotherapy.
4 matic disease sites as well as intra-CSF and systemic chemotherapy.
5 anced pancreatic NETs after failure of prior systemic chemotherapy.
6 f patients are spared the adverse effects of systemic chemotherapy.
7 and radiographic complete remission (CR) to systemic chemotherapy.
8 laced by intensive intrathecal treatment and systemic chemotherapy.
9 reduction in febrile neutropenia (FN) after systemic chemotherapy.
10 prove the selection of patients for adjuvant systemic chemotherapy.
11 umoral injections of rF-mCD40L together with systemic chemotherapy.
12 e patients, the asymptomatic BM responded to systemic chemotherapy.
13 (at diagnosis of SCLC) and after first-line systemic chemotherapy.
14 small-cell lung cancer (SCLC) to first-line systemic chemotherapy.
15 ed therapy with cystectomy and perioperative systemic chemotherapy.
16 d less than a quarter of patients respond to systemic chemotherapy.
17 on, given the improvement in the efficacy of systemic chemotherapy.
18 ume of the brain and spine), with or without systemic chemotherapy.
19 ntriculoatrial shunts, prior craniotomy, and systemic chemotherapy.
20 agent in NSCLC should be in combination with systemic chemotherapy.
21 ents who underwent surgery and postoperative systemic chemotherapy.
22 long-term cognitive deficits associated with systemic chemotherapy.
23 who received both surgery and postoperative systemic chemotherapy.
24 asome inhibition as an important adjuvant to systemic chemotherapy.
25 irty-three patients (75%) had received prior systemic chemotherapy.
26 sed patient with HCC had previously received systemic chemotherapy.
27 lized disease, (2) interferon-alpha, and (3) systemic chemotherapy.
28 primary site; more recently, it has included systemic chemotherapy.
29 ents had progressive disease following prior systemic chemotherapy.
30 chemotherapy and two more cycles of the same systemic chemotherapy.
31 up C, development of brain metastases during systemic chemotherapy.
32 volumes to higher doses in conjunction with systemic chemotherapy.
33 atment that includes surgery, radiation, and systemic chemotherapy.
34 tempered by altering the dosing schedule of systemic chemotherapy.
35 ed efficacy and reduced toxicity compared to systemic chemotherapy.
36 apeutic concentration at the tumor site with systemic chemotherapy.
37 ients with the goal of providing time off of systemic chemotherapy.
38 metastases in patients receiving first-line systemic chemotherapy.
39 who received HAI also received perioperative systemic chemotherapy.
40 as shown multifarious advantages compared to systemic chemotherapy.
41 r patients with TRIL who have received prior systemic chemotherapy.
42 disease, implications for surveillance, and systemic chemotherapy.
43 ecific likelihood of receiving postoperative systemic chemotherapy.
44 A total of 40 patients received systemic chemotherapy.
45 redict the response of human lung cancers to systemic chemotherapy.
46 ant chemotherapy also received postoperative systemic chemotherapy.
47 ents, despite the administration of adjuvant systemic chemotherapy.
48 ression reduction (IR) followed by immediate systemic chemotherapy.
49 ersus >/= 25%); 2) prior platinum-containing systemic chemotherapy; 3) embolization of segments 5-8 v
52 Postoperative HAI oxaliplatin combined with systemic chemotherapy after curatively intended surgery
56 T FINDINGS: Improved prognosis compared with systemic chemotherapy alone has recently been demonstrat
57 Factors associated with achieving CR with systemic chemotherapy alone included FOLFOX4 treatment,
59 and intraperitoneal chemotherapy (IPC) over systemic chemotherapy alone, the treatment of peritoneal
62 percent in the group treated with local plus systemic chemotherapy and 72 percent in the group given
63 treatment of the CNS included both high-dose systemic chemotherapy and intrathecal therapy, in contra
65 ents who had failed to respond adequately to systemic chemotherapy and local treatment where appropri
67 therapy were randomized to receive intensive systemic chemotherapy and presymptomatic CNS therapy tha
69 ciation was independent of the use of modern systemic chemotherapy and remained in propensity score a
70 ced non-small cell lung cancer has been with systemic chemotherapy and usually consists of a platinum
71 tes of extracranial disease who failed early systemic chemotherapy and were able to receive SBRT and
74 to relieve pain when used concurrently with systemic chemotherapy and/or hormonal therapy, since it
75 patients enrolled, 117 had received no prior systemic chemotherapy, and 34 had received prior chemoth
76 and antibody therapies such as alemtuzumab, systemic chemotherapy, and allogeneic transplantation.
77 ternal beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90
79 for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who
80 bidities, and treatment modalities including systemic chemotherapy, antiangiogenic therapy, and hospi
84 e to target these pathways concurrently with systemic chemotherapy as a strategy to improve the clini
85 er received significantly more postoperative systemic chemotherapy at all stages, but they experience
88 cancer or lymphoma who had been treated with systemic chemotherapy (breast, n = 141, age = 57.0 +/- 1
90 e the risk of subsequent metastatic disease, systemic chemotherapy can be introduced early during the
91 from this study support the hypothesis that systemic chemotherapy can have a negative impact on cogn
92 l injection of CpG oligodeoxynucleotide plus systemic chemotherapy can induce a T-cell immune respons
93 ase II trials have demonstrated tolerance to systemic chemotherapy; chemotherapy plus radiation prior
94 oma even in localized disease whereas IR and systemic chemotherapy (CHOP-21) could achieve lasting co
95 nal Cancer Data Base who received multiagent systemic chemotherapy combined with high-intensity versu
96 8 times more likely to receive postoperative systemic chemotherapy compared with older patients (65-7
98 of patients and fewer patients who received systemic chemotherapy developed pineoblastoma, possibly
100 l mucin debulking, adenocarcinoma histology, systemic chemotherapy, diffuse IP disease at presentatio
102 otrexate, as well as the roles of additional systemic chemotherapy drugs, intrathecal therapy, and cr
103 to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to identify a g
104 treated with OAC after prior treatment with systemic chemotherapy, external beam radiation, or both
105 ents received two cycles of bolus 5-FU-based systemic chemotherapy followed by pelvic radiation thera
113 with an improved survival, as compared with systemic chemotherapy for peritoneal carcinomatosis from
119 univariate analysis, the use of neoadjuvant systemic chemotherapy had a significant positive prognos
124 cancer (CRC) can be rendered resectable with systemic chemotherapy in approximately 20% of cases.
125 rove survival, advances have been made using systemic chemotherapy in both the perioperative settings
126 h IT mafosfamide administered with intensive systemic chemotherapy in children younger than 3 years w
127 Evidence supports the safety and efficacy of systemic chemotherapy in fit older patients motivated en
128 mersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma
130 s with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain.
132 erial chemoembolization and/or perioperative systemic chemotherapy in the treatment of advanced HCC t
133 c antibody in combination with standard-dose systemic chemotherapy in the treatment of indolent B-cel
134 be beneficial for monitoring the success of systemic chemotherapy in the treatment of various tubero
135 ions of this disease, as well as the role of systemic chemotherapy in treatment of unresectable disea
136 patients (75%) were treated with neoadjuvant systemic chemotherapy in whom 32 (36%) were considered t
139 FUDR plus dexamethasone (Dex) and concurrent systemic chemotherapy including oxaliplatin or irinoteca
140 Localized disease was treated with combined systemic chemotherapy, including rituximab and radiation
142 ectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging
147 nt of the disease and understand response to systemic chemotherapy is limited with current imaging ap
148 However, there is general agreement that systemic chemotherapy is rarely an effective form of man
152 th an isolated CNS relapse were treated with systemic chemotherapy known to enter into the CSF and in
153 AIDS-related Kaposi's sarcoma (AIDS-KS) with systemic chemotherapy, less toxic therapies are needed.
154 ansitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatme
155 trinsic resistance of melanoma metastases to systemic chemotherapy may be due, in part, to the cells'
161 ients who received surgery and postoperative systemic chemotherapy, no significant differences were o
163 ctreotide, interferon, and both arterial and systemic chemotherapy, of which only chemoembolisation i
164 was to evaluate the influence of neoadjuvant systemic chemotherapy on patients with colorectal carcin
166 dvanced RCC treated on 24 clinical trials of systemic chemotherapy or cytokine therapy were the subje
169 t of 15 HIV-1-infected individuals receiving systemic chemotherapy or subsequent autologous stem cell
170 those recurrent after surgery, radiotherapy, systemic chemotherapy, or topical chemotherapy) vs treat
171 , young patients were more likely to receive systemic chemotherapy, particularly multiagent regimens,
172 INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (
176 urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and h
180 led that survivors who had been treated with systemic chemotherapy scored significantly lower on over
181 led that survivors who had been treated with systemic chemotherapy scored significantly lower on the
183 eritoneal metastases, failure of neoadjuvant systemic chemotherapy should not constitute an absolute
184 chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and p
185 domized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progr
187 traocular retinoblastomas after radiation or systemic chemotherapy than has been reported in the lite
188 ven via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barri
189 solated CNS relapse of ALL were treated with systemic chemotherapy that effectively penetrates into t
191 occurred in 9 of 40 (23%) patients receiving systemic chemotherapy; the most common of these effects
192 fin photodynamic therapy in combination with systemic chemotherapy therapies and oral corticosteroids
193 noma, no resection of the primary tumor, and systemic chemotherapy, this study investigated the incid
195 d in association with concomitant multiagent systemic chemotherapy to children younger than 3 years w
196 the COX2 and YAP1 pathways concurrently with systemic chemotherapy to improve the clinical management
197 ples from patients that have been exposed to systemic chemotherapy to infer the genomic landscape of
200 tance and toxicities often limit benefits of systemic chemotherapy used to treat metastatic sarcomas.
201 with Reese-Ellsworth eye groups 1, 2, or 3, systemic chemotherapy used with local ophthalmic therapi
202 floxuridine (HAI-FUDR) in addition to modern systemic chemotherapy using oxaliplatin or irinotecan re
205 on, the combination of dl1520 infection with systemic chemotherapy was assessed in these tumor xenogr
207 of SIR-Spheres therapy with modified FOLFOX4 systemic chemotherapy was conducted in patients with ino
208 s of patients with isolated PVRL, the use of systemic chemotherapy was not proven to prevent CNSL and
209 until no further benefit could be achieved; systemic chemotherapy was sometimes used as a palliative
212 rty-four patients who had not received prior systemic chemotherapy were randomized to either arm of t
213 cer who had not been previously treated with systemic chemotherapy were recruited from 91 academic me
214 completeness of CRS and the use of adjuvant systemic chemotherapy were the only significant prognost
215 bladder has traditionally been treated with systemic chemotherapy, which is most often platinum-base
216 e but applicable to only a few patients, and systemic chemotherapy, which is of uncertain benefit but
217 , extended intrathecal therapy and intensive systemic chemotherapy will, in all likelihood, replace c
218 tumors of the gynecologic tract will require systemic chemotherapy with a platinum agent and etoposid
220 entral nervous system lymphoma are employing systemic chemotherapy with drugs that penetrate the bloo
224 le disease, consideration should be given to systemic chemotherapy with or without a biologic agent o
226 roaches based on the site of malignancy, but systemic chemotherapy with or without radiation plays a
227 with HAI floxuridine and dexamethasone plus systemic chemotherapy with oxaliplatin and irinotecan.
229 tal radiation of 30 gray in conjunction with systemic chemotherapy with rituximab can achieve disease
230 re randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to ass
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。